Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 24 Triple Negative Breast Neoplasms 11 Breast Neoplasms 10 Carcinoma, Transitional Cell 9 Small Cell Lung Carcinoma 7 Carcinoma, Renal Cell 7 Carcinoma, Hepatocellular 7 Neoplasm Metastasis 6 Melanoma 6 Colorectal Neoplasms 6 Lung Neoplasms 5 Recurrence 4 Neoplasms 4 Urinary Bladder Neoplasms 3 Lymphoma, B-Cell 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Kidney Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Merkel Cell 2 Brain Neoplasms 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urologic Diseases 1

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × atezolizumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡